Subgroup analyses revealed that lecanemab had a more pronounced effect in slowing cognitive decline in individuals who are ApoE ε4 noncarriers compared to carriers and had the least impact on participants who were ApoE ε4 homozygotes. Here, APOE is linked to Mental deterioration.